TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11896937

Group type: EXPERIMENTAL
Intervention: E. coli Nissle 1917
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 10535335

Group type: EXPERIMENTAL
Intervention: Iron supplementation of 65 mg/day from 20 weeks of gestation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 7774471

Group type: EXPERIMENTAL
Intervention: Nasogastric decompression (NG)
Number of subjects: 480

Group type: COMPARATOR
Intervention: No nasogastric decompression (NG)
Number of subjects: 480
Study: 1620169

Group type: EXPERIMENTAL
Intervention: Ritodrine (n = 352)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Placebo (n = 356)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 708
Study: 6381065

Group type: EXPERIMENTAL
Intervention: Intravenous and oral mexiletine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (lignocaine supplemented)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide
Number of subjects: 240
Study: 31386660

Group type: EXPERIMENTAL
Intervention: MMN
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: MMN + PE
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: PE
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: PE + MMN
Number of subjects: 875
Study: 30189612

Group type: EXPERIMENTAL
Intervention: Colostrum (3.16 g/L)
Number of subjects: 6481

Group type: EXPERIMENTAL
Intervention: Transitional milk (1.73 g/L)
Number of subjects: 6481

Group type: EXPERIMENTAL
Intervention: Mature milk (0.90 g/L)
Number of subjects: 6481

Group type: EXPERIMENTAL
Intervention: Geographical comparison (Guangdong 1.91 g/L)
Number of subjects: 6481

Group type: EXPERIMENTAL
Intervention: Ethnicity comparison (Dai 1.80 g/L)
Number of subjects: 6481

Group type: EXPERIMENTAL
Intervention: Ethnicity comparison (Han 1.62 g/L)
Number of subjects: 6481
Study: 26309191

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic (300 μg recombinant MAGE-A3 formulated with AS15) administered concurrently with standard cisplatin/vinorelbine chemotherapy (cohort 1)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic administered after standard chemotherapy (cohort 2)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic administered without standard chemotherapy (cohort 3)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MAGE-A3 immunotherapeutic administered after standard radiotherapy and/or chemotherapy (cohort 4)
Number of subjects: 67
Study: 23872605

Group type: EXPERIMENTAL
Intervention: Albumin (1.5g/kg on day 1 and 1.0g/kg on day 3)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline (isotonic saline)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 56
Study: 21817947

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 50 mg/d for 5 days with tapering of doses for the next 5 days, alternatively with intravenous betamethasone 8 mg on the first 1 to 2 days if nauseated
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (historic untreated)
Number of subjects: 33
Study: 19401664

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol (2 mg/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Peritonsillar infiltration of tramadol (2 mg/kg in 2 ml normal saline)
Number of subjects: 66
Study: 16731324

Group type: EXPERIMENTAL
Intervention: Clonidine-ephedrine (CE)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clonidine-saline (CS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diazepam-ephedrine (DE)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Diazepam-saline (DS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clonidine-ephedrine (CE) and Clonidine-saline (CS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ephedrine (in CE and DE)
Number of subjects: 200
Study: 15523663

Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation containing folic acid (0.8 mg)
Number of subjects: 3056

Group type: COMPARATOR
Intervention: Unsupplemented cohort
Number of subjects: 3056
Study: 11736724

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily for 8 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg daily for 8 days)
Number of subjects: 15
Study: 9369816

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution with 5% glucose (n = 48)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Lactated Ringer's solution without glucose (n = 43)
Number of subjects: 91
Study: 1357701

Group type: EXPERIMENTAL
Intervention: Ceruletide (0.8 microgram/kg, once-weekly i.m. injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2866117

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Naproxen-sodium
Number of subjects: 57
Study: 31136450

Group type: EXPERIMENTAL
Intervention: Exergaming-based dexterity training (30 minutes, twice a week for 4 weeks)
Number of subjects: 10
Study: 29563377

Group type: EXPERIMENTAL
Intervention: Bivalirudin (standard usage)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Bivalirudin (with heparin added in decreasing amounts)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Bivalirudin (additional bolus)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Heparin (bolus)
Number of subjects: 117
Study: 26590384

Group type: EXPERIMENTAL
Intervention: Blood pressure <140/90 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure <130/80 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean on-treatment SBP 130-139 mmHg or DBP 80-89 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean on-treatment SBP <130 mmHg or DBP <80 mmHg
Number of subjects: 0
Study: 24237691

Group type: EXPERIMENTAL
Intervention: Yohimbine HCl (10.8 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21972179

Group type: EXPERIMENTAL
Intervention: Controllable painful electric skin stimuli
Number of subjects: 64

Group type: COMPARATOR
Intervention: Uncontrollable painful electric skin stimuli
Number of subjects: 64
Study: 20042310

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cetuximab with capecitabine-based chemoradiotherapy (CRT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cetuximab with capecitabine-based CRT
Number of subjects: 37
Study: 18568228

Group type: EXPERIMENTAL
Intervention: Chemical treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sandblasting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mechanical treatment - 0.4 mm beads
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mechanical treatment - 0.6 mm beads
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chemical/mechanical treatment - 0.4 mm beads
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chemical/mechanical treatment - 0.6 mm beads
Number of subjects: 30
Study: 16238901

Group type: EXPERIMENTAL
Intervention: 1 mg intravenous test dose of paclitaxel or docetaxel
Number of subjects: 218

Group type: COMPARATOR
Intervention: Full dose of paclitaxel or docetaxel without a test dose
Number of subjects: 218
Study: 11908576

Group type: EXPERIMENTAL
Intervention: Fitness program (n = 58)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Biofeedback training (n = 56)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual care (Control group, n = 29)
Number of subjects: 143
Study: 9923505

Group type: EXPERIMENTAL
Intervention: NaF/triclosan/Gantrez dentifrice slurry (1 ml mixed with 10 ml tap water)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NaF/triclosan/Gantrez mouthrinse (10 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NaF mouthrinse (10 ml)
Number of subjects: 10
Study: 7579056

Group type: EXPERIMENTAL
Intervention: Cyclosporine monotherapy (CsA)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Withdrawal of Pred in CsA group
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Retreatment with Pred
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Prednisone (Pred) use
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) use
Number of subjects: 122
Study: 2284832

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing containing anthralin (0.02 to 0.20 mg/cm2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-contact therapy with anthralin alone
Number of subjects: 0
Study: 500259

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31828962

Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI)
Number of subjects: 417
Study: 31627478

Group type: EXPERIMENTAL
Intervention: Oily fish consumption
Number of subjects: 20670
Study: 28492711

Group type: EXPERIMENTAL
Intervention: Triple therapy with curcumin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 0
Study: 25634195

Group type: EXPERIMENTAL
Intervention: 3-L split-dose PEG
Number of subjects: 318

Group type: COMPARATOR
Intervention: 2-L PEG
Number of subjects: 318
Study: 23249342

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21136272

Group type: EXPERIMENTAL
Intervention: Intervention group (IG) received the CPG‐PD with special instructions, a 4‐h training, and personal feedback.
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control group (CG) did not receive the same intervention as IG.
Number of subjects: 386
Study: 19305145

Group type: EXPERIMENTAL
Intervention: VARIVAX
Number of subjects: 507

Group type: COMPARATOR
Intervention: M-M-R II
Number of subjects: 507
Study: 17242626

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 15651179

Group type: EXPERIMENTAL
Intervention: Combination of amphotericin B and fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echinocandins in combination with triazoles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of echinocandin to monotherapy for aspergillosis
Number of subjects: 0
Study: 12166510

Group type: EXPERIMENTAL
Intervention: losartan 50 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no specific antiproteinuric treatment)
Number of subjects: 44
Study: 9756589

Group type: EXPERIMENTAL
Intervention: Deep acupuncture treatment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Superficial acupuncture treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: No acupuncture treatment (control group)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Conventional stroke rehabilitation
Number of subjects: 104
Study: 8110006

Group type: EXPERIMENTAL
Intervention: Hypotonic ORS with citrate
Number of subjects: 107

Group type: COMPARATOR
Intervention: Hypotonic ORS without citrate
Number of subjects: 107
Study: 3276933

Group type: EXPERIMENTAL
Intervention: Saphenous vein patching
Number of subjects: 129

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 129

Group type: COMPARATOR
Intervention: Primary closure in women
Number of subjects: 129

Group type: COMPARATOR
Intervention: Primary closure in men
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Patching in men
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Patching in women
Number of subjects: 129
Study: 31828291

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent vaccine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-dose trivalent vaccine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Recombinant-hemagglutinin (rHA) quadrivalent vaccine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent vaccine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Enhanced vaccines
Number of subjects: 200
Study: 29303039

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 255
Study: 28743491

Group type: EXPERIMENTAL
Intervention: Surgical score based on liver stiffness, BILCHE score, type of hepatectomy, and presence of varices
Number of subjects: 340
Study: 25061062

Group type: EXPERIMENTAL
Intervention: Single injection of 4 mL of 1% lignocaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Repetitive injection of 4 mL of 1% lignocaine twice a week for 2 weeks
Number of subjects: 42
Study: 24012360

Group type: EXPERIMENTAL
Intervention: Single-row technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Double-row suture bridge technique
Number of subjects: 90
Study: 20805274

Group type: EXPERIMENTAL
Intervention: 0.25 microg/day calcitriol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Calcitriol and Placebo
Number of subjects: 34
Study: 17976882

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy volunteers (n=45; 19 males and 26 females)
Number of subjects: 100
Study: 15992422

Group type: EXPERIMENTAL
Intervention: 50 mg doxorubicin
Number of subjects: 82

Group type: COMPARATOR
Intervention: No adjuvant therapy (control group)
Number of subjects: 82
Study: 12851511

Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (2 mg daily of 17beta-estradiol plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (50 microg daily of 17beta-estradiol plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Calcium supplementation (control group)
Number of subjects: 75
Study: 10541423

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg QD
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 180 mg QD
Number of subjects: 845

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 845
Study: 9084323

Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorbitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both xylitol and sorbitol
Number of subjects: 0
Study: 1920093

Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 7295487

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 33
Study: 30844639

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (bCBT)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 302
Study: 28623320

Group type: EXPERIMENTAL
Intervention: Lactose-based infant formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSS-based infant formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 0
Study: 25865762

Group type: EXPERIMENTAL
Intervention: Geometric bicuspid annuloplasty ring
Number of subjects: 16
Study: 23331817

Group type: EXPERIMENTAL
Intervention: Single umbilical incision laparoscopic cholecystectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4-port laparoscopic cholecystectomy
Number of subjects: 60
Study: 21406001

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) procedure
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 23
Study: 19320663

Group type: EXPERIMENTAL
Intervention: Inhaled insulin three times daily before meals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Insulin glargine administered in the morning before breakfast
Number of subjects: 40
Study: 17122220

Group type: EXPERIMENTAL
Intervention: Lidocaine (Group L)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ketamine 100 microg/kg (Group K100)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Midazolam premedication (Group M)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ketamine mixed with propofol (Group KP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ketamine administered 3 min before propofol (Group Pre)
Number of subjects: 240
Study: 15500817

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Programmed generalization condition
Number of subjects: 40
Study: 11239727

Group type: EXPERIMENTAL
Intervention: 6-session cognitive-behavioral therapy (CBT) program
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Single-session brief intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 229
Study: 9402774

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide 50 micrograms twice daily for 6 months with programmed injection sclerotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Programmed injection sclerotherapy alone
Number of subjects: 32
Study: 8500239

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 804

Group type: COMPARATOR
Intervention: Hydralazine‐isosorbide dinitrate
Number of subjects: 804
Study: 3502138

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine (2 mg i.v.)
Number of subjects: 0
Study: 31628873

Group type: EXPERIMENTAL
Intervention: Guided virtual surgery (stereolithographic guides)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional surgery (conventional guides)
Number of subjects: 12
Study: 30522512

Group type: EXPERIMENTAL
Intervention: Oral health intervention including oral health education sessions and daily oral self-care under caregiver supervision.
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control group (children living with HIV receiving standard care).
Number of subjects: 520

Group type: COMPARATOR
Intervention: Control group (HIV-uninfected children age-matched to the intervention group).
Number of subjects: 520
Study: 27397927

Group type: EXPERIMENTAL
Intervention: True air purifiers
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham air purifiers
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PM2.5 exposure (IQR increase of 64μg/m(3))
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PM2.5 exposure
Number of subjects: 35
Study: 24795200

Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir and dasabuvir with ribavirin
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir and dasabuvir without ribavirin
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: ABT-450/r-ombitasvir and dasabuvir with or without ribavirin
Number of subjects: 724
Study: 22820824

Group type: EXPERIMENTAL
Intervention: Deep heating therapy (DHT) via local microwave diathermy (three 30‐min sessions a week for four weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Superficial heating therapy (SHT) via application of hot packs (three 30‐min sessions a week for four weeks)
Number of subjects: 54
Study: 20478022

Group type: EXPERIMENTAL
Intervention: Pathways Advisory Service intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cluster randomised controlled trial design
Number of subjects: 0
Study: 17302873

Group type: EXPERIMENTAL
Intervention: Intracortical inhibition (ICI) during anovulatory cycles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intracortical inhibition (ICI) on day -14, -7, and 2 during anovulatory cycles
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intracortical inhibition (ICI) in ovulatory cycles
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resting motor threshold (RMT), cortical silent period (CSP), and intracortical facilitation (ICF)
Number of subjects: 20
Study: 14657456

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting with cerebral protection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Carotid angioplasty and stenting without cerebral protection
Number of subjects: 80
Study: 11680556

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Behavioral Counseling plus Exercise (BEX)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Behavioral Counseling plus Nicotine Gum (BNIC)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 1-year follow-up
Number of subjects: 205
Study: 9441728

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8204511

Group type: EXPERIMENTAL
Intervention: LOPP alternating with EVAP regimen
Number of subjects: 160

Group type: COMPARATOR
Intervention: LOPP/EVA hybrid regimen
Number of subjects: 160
Study: 2455170

Group type: EXPERIMENTAL
Intervention: Low-dose clonidine (0.075 mg per day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (nontreated)
Number of subjects: 28
Study: 28355957

Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 29

Group type: COMPARATOR
Intervention: Satiated (fed) state
Number of subjects: 29
Study: 27446961

Group type: EXPERIMENTAL
Intervention: Computer-based self-management program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 70
Study: 24952581

Group type: EXPERIMENTAL
Intervention: Physiotherapy exercises
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Occupational medical assistance
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Physiotherapy exercises and occupational medical assistance
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 23185342

Group type: EXPERIMENTAL
Intervention: Single re-exposition to the conditioned stimulus (CS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Four re-expositions to the conditioned stimulus (CS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Expectation of taking an immunosuppressant
Number of subjects: 26
Study: 21095277

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25OHD) concentration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire physical limitation domain score
Number of subjects: 40
Study: 18454426

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 80